Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM1A | O60341 | 5/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SAT1 | P21673 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5932747 | 0.86 | MEN1 (0.48) | MEN1KMT2ACYP2C19ALDH1A1KDM4E | |
| SCHEMBL172548 | 0.82 | MEN1 (0.40) | MEN1KMT2ACYP2C19TSHRALDH1A1 | |
| SCHEMBL20582715 | 0.78 | CYP2C19 (0.35) | MEN1KMT2ACYP2C19GLACYP1A2 | |
| SCHEMBL27650384 | 0.78 | TSHR (0.46) | MEN1KMT2ACYP2C19GLACYP1A2 | |
| SCHEMBL15467596 | 0.77 | CYP2C19 (0.38) | MEN1KMT2ACYP2C19GLACYP1A2 | |
| SCHEMBL22479347 | 0.77 | MEN1 (0.40) | MEN1KMT2ACYP2C19CYP1A2ALDH1A1 | |
| SCHEMBL26274264 | 0.77 | MEN1 (0.40) | MEN1KMT2ACYP2C19ALDH1A1KDM4E | |
| SCHEMBL13996765 | 0.77 | MEN1 (0.40) | MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL27414420 | 0.77 | — | — | |
| SCHEMBL24837512 | 0.77 | MEN1 (0.36) | MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100374196-C | Method for producing polyisocyanates | BASF AG (DE) | 2008-03-12 | — | — | CN | claimed |
| CN-1758956-A | Method for producing polyisocyanates | BASF AG (DE) | 2006-04-12 | — | — | CN | claimed |
| CN-109476612-A | Catalyst for curable compositions comprising hexahydrotriazine structural units | SIKA技术股份公司 | 2019-03-15 | — | — | CN | disclosed |
| EP-2678349-B1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | TAISHO PHARMACEUTICAL CO LTD (JP) | 2016-01-13 | — | — | EP | disclosed |
| US-9139609-B2 | C-4″ position substituted macrolide derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-09-22 | — | — | US | disclosed |
| CN-101748117-B | Sample dissociation and coating of reaction surface | QIAGEN GMBH | 2014-03-26 | — | — | CN | disclosed |
| US-20140046043-A1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-02-13 | — | — | US | disclosed |
| US-20100249145-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signaling | METHYLGENE, INC. | 2010-09-30 | — | — | US | disclosed |
| US-7790729-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2010-09-07 | — | — | US | disclosed |
| US-20100216766-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signalling | 92229129 QUEBEC INC. (CA) | 2010-08-26 | — | — | US | disclosed |
| CN-101748117-A | Sample dissociation and coating of reaction surface | QIAGEN GMBH | 2010-06-23 | — | — | CN | disclosed |
| CN-1758956-A | Method for producing polyisocyanates | BASF AG (DE) | 2006-04-12 | — | — | CN | disclosed |
| CN-1675195-A | Tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2005-09-28 | — | — | CN | disclosed |
| CN-1599764-A | Compounds suitable as dispersion agent for pigments | BASF AG (DE) | 2005-03-23 | — | — | CN | disclosed |
| US-5618814-A | Trisubstituted pyrimido [5,4-d] pyrimidines for modulating multi-drug resistance and pharmaceutical compositions containing these compounds | DR. KARL THOMAE GMBH (DE) | 1997-04-08 | — | — | US | disclosed |
| US-5348953-A | Elastase inhibitor | MERCK & CO., INC. (US) | 1994-09-20 | — | — | US | disclosed |
| WO-1994013636-A1 | NEW SUBSTITUTED AZETIDINONES AS ANTI-INFLAMMATORY AND ANTIDEGENERATIVE AGENTS | MERCK & CO., INC. (US) | 1994-06-23 | — | — | WO | disclosed |
| EP-0525973-A2 | Substituted azetidinones as anti-inflammatory and antidegenerative agents | MERCK & CO. INC. (US) | 1993-02-03 | — | — | EP | disclosed |
| WO-1993000332-A1 | SUBSTITUTED AZETIDINONES AS ANTI-INFLAMMATORY AND ANTIDEGENERATIVE AGENTS | MERCK & CO., INC. (US) | 1993-01-07 | — | — | WO | disclosed |
| CN-1043700-A | The compound that is used for the treatment of the urinary incontinence | PHARMACIA AB (SE) | 1990-07-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249145-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signaling | HGF, MET, FLT1 | MEN1 3655/4885KMT2A 3391/4885CYP2C19 4590/4885 |
| US-20100216766-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signalling | HGF, MET, FLT1 | MEN1 3623/4885KMT2A 3438/4885CYP2C19 4595/4885 |
| US-20140046043-A1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | MRPL21, MRPS34, MRPL37 | MEN1 1302/4885KMT2A 3170/4885CYP2C19 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.